Karyopharm raises $165M in PIPE; sells 31.8M shares at $5.19 with warrants

Karyopharm Therapeutics Inc.

Gross proceeds ~$165M from sale of 31,791,908 shares at $5.19 and warrants for 9,537,563 shares at $6.36.
Lead investors include Avidity Partners, Adage Capital, Armistice Capital, and others; expected close Dec 7, 2022.
Proceeds to fund selinexor and eltanexor clinical programs, working capital; cash runway extended into late 2025.
Warrants exercisable for five years after closing; registration statement for resale to be filed within 30 days.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $165 million (effective 2022-12-05).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $165 million
Effective: 2022-12-05

Exact text from the filing

On December 5, 2022, Karyopharm Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement an aggregate of (i) 31,791,908 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and (ii) accompanying warrants (the “ Warrants ”) to purchase up to 9,537,563 shares of Common Stock (collectively, the “ Private Placement ”).

View on SEC.gov

33 material agreements filed in the last 30 days. Browse all material agreements →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-298052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.